KBP-COVID-19 + CpG adjuvant

KBP-COVID-19 + CpG adjuvant is a **COVID-19 vaccine candidate** composed of the KBP-COVID-19 antigen with a **CpG oligonucleotide adjuvant**. The vaccine is being investigated for its ability to induce strong humoral and cellular immune responses. CpG adjuvants activate innate immunity via Toll-like receptor 9 (TLR9) in the endosome, skewing the adaptive immune response toward a Th1 phenotype that promotes high neutralizing antibody titers and robust CD8+ T cell activation[1][2][3][4]. Preclinical and early-stage clinical studies show the combination elicits potent antibody and T cell responses in animal models and humans[2][3]. KBP, likely KBio, is developing and sourcing the vaccine, which is tested in healthy adults in observer-blinded, randomized, placebo-controlled trials[3][5]. Primary indication is **prevention of COVID-19**.

Other names

KBP-COVID-19 plus CpG adjuvantKBP-COVID19 plus CpG adjuvantKBP-COVID 19 plus CpG adjuvantKBP-COVID-19 CpG-adjuvanted vaccineKBP-COVID19 CpG-adjuvanted vaccineKBP-COVID 19 CpG-adjuvanted vaccine